Pregnancy: There are limited data from the use of Empagliflozin (Jardiance) in pregnant women. Nonclinical studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure it is recommended to avoid the use of Empagliflozin (Jardiance) during pregnancy unless clearly needed.
Lactation: No data in humans are available on excretion of empagliflozin into milk. Available nonclinical data in animals have shown excretion of empagliflozin in milk. A risk to human newborns/infants cannot be excluded. It is recommended to discontinue breast feeding during treatment with Empagliflozin (Jardiance).
Fertility: No studies on the effect on human fertility have been conducted for Empagliflozin (Jardiance). Nonclinical studies in animals do not indicate direct or indirect harmful effects with respect to fertility.
Other Services
Country
Account